1. Tamaki N. Guidelines for clinical use of cardiac nuclear medicine (JCS 2005). Circ J. 2005; 69(Suppl IV):1125–1202.
2. Nakajima K, Nakata T. Cardiac
123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan. J Nucl Med. 2015; 56(Suppl 4):11S–19S. PMID:
26033897.
3. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006; 9(3 Suppl):417–423. PMID:
16914880.
4. Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014; 21:970–978. PMID:
24942608.
5. Slomka PJ, Mehta PK, Germano G, Berman DS. Quantification of I-123-meta-iodobenzylguanidine heart-to-mediastinum ratios: not so simple after all. J Nucl Cardiol. 2014; 21:979–983. PMID:
25005347.
6. Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging. 2008; 52:378–387. PMID:
19088692.
7. Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, et al. Proposal for standardization of
123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010; 37:1802–1812. PMID:
20577740.
8. Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BL, Busemann Sokole E. Influence of collimator choice and simulated clinical conditions on
123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging. 2005; 32:1100–1107. PMID:
15902438.
9. Nakajima K, Matsubara K, Ishikawa T, Motomura N, Maeda R, Akhter N, et al. Correction of iodine-
123-labeled meta-iodobenzylguanidine uptake with multi-window methods for standardization of the heart-to-mediastinum ratio. J Nucl Cardiol. 2007; 14:843–851. PMID:
18022111.
10. Nakajima K, Matsumoto N, Kasai T, Matsuo S, Kiso K, Okuda K. Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med. 2016; 30:188–199. PMID:
26897008.
11. Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-
123 MIBG imaging. J Nucl Cardiol. 2011; 18:82–89. PMID:
21104360.
12. Okuda K, Nakajima K, Sugino S, Kirihara Y, Matsuo S, Taki J, et al. Development and validation of a direct-comparison method for cardiac
123I-metaiodobenzylguanidine washout rates derived from late 3-hour and 4-hour imaging. Eur J Nucl Med Mol Imaging. 2016; 43:319–325. PMID:
26298280.
13. Verberne HJ, Habraken JB, van Eck-Smit BL, Agostini D, Jacobson AF. Variations in
123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging. 2008; 35:547–553. PMID:
17922122.
14. Nakajima K, Okuda K, Matsuo S, Yoshita M, Taki J, Yamada M, et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging. 2012; 39:113–119. PMID:
22009380.
15. Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S, et al. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using
123I-metaiodobenzylguanidine imaging. Eur J Nucl Med Mol Imaging. 2014; 41:1673–1682. PMID:
24663289.
16. Nakajima K, Nakata T, Matsuo S, Jacobson AF. Creation of mortalityrisk charts using
123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models. Eur Heart J Cardiovasc Imaging. 2015; [Epub ahead of print]. DOI:
10.1093/ehjci/jev322.
17. Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, et al. A radiological analysis of heart sympathetic functions with meta-[
123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1994; 49:81–84. PMID:
7963268.
18. Iwasa K, Nakajima K, Yoshikawa H, Tada A, Taki J, Takamori M. Decreased myocardial
123I-MIBG uptake in Parkinson's disease. Acta Neurol Scand. 1998; 97:303–306. PMID:
9613559.
19. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-
123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998; 155:60–67. PMID:
9562324.
20. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H.
123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999; 67:189–194. PMID:
10406987.
21. Orimo S, Suzuki M, Inaba A, Mizusawa H.
123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012; 18:494–500. PMID:
22321865.
22. Yoshita M, Taki J, Yamada M. A clinical role for [
123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001; 71:583–588. PMID:
11606666.
23. Watanabe H, Ieda T, Katayama T, Takeda A, Aiba I, Doyu M, et al. Cardiac
123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001; 70:781–783. PMID:
11385013.
24. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65:1863–1872. PMID:
16237129.
25. Hanyu H, Shimizu S, Hirao K, Kanetaka H, Iwamoto T, Chikamori T, et al. Comparative value of brain perfusion SPECT and [
123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2006; 33:248–253. PMID:
16328506.
26. Sakamoto F, Shiraishi S, Yoshida M, Tomiguchi S, Hirai T, Namimoto T, et al. Diagnosis of dementia with Lewy bodies: diagnostic performance of combined
123I-IMP brain perfusion SPECT and
123I-MIBG myocardial scintigraphy. Ann Nucl Med. 2014; 28:203–211. PMID:
24363079.
27. Yoshita M, Arai H, Arai H, Arai T, Asada T, Fujishiro H, et al. Diagnostic accuracy of
123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One. 2015; 10:e0120540. PMID:
25793585.
28. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-
123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010; 55:2212–2221. PMID:
20188504.
29. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of
123I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013; 6:772–784. PMID:
23845574.
30. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008; 35:535–546. PMID:
18043919.
31. King AE, Mintz J, Royall DR. Meta-analysis of
123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord. 2011; 26:1218–1224. PMID:
21480373.
32. Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [
123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006; 33:1491–1499. PMID:
16858570.